Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenersen plus chemotherapy versus placebo plus chemotherapy in older patients with refractory acute myeloid leukemia
2008-002160-34Phase 2Terminated
- Sponsor
- Eleos Health
- Start
- Sep 2008
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Cenersen + chemotherapy with Placebo + chemotherapy (2 arms). Primary endpoint: Complete Remission (CR) Rate. Started Sep 2008; status: terminated.
02
Drugs
cenersen sodium
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2008-002160-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002160-34.